For free samples, call 1-866-318-6977

For free samples, call 1-866-318-6977

RESOURCES FOR PATIENTS
GETTING STARTED ON COSENTYX

This comprehensive list of resources and videos will help guide patients through the process of getting started on COSENTYX

This comprehensive list of resources and videos will help guide patients through the process of getting started on COSENTYX

Patient Medisafe App Card

Patient Medisafe App Card

Learn about the variety of patient services offered through the Medisafe app, including refill reminders and medication tracking.

COSENTYX Patient Enrollment Tearsheet

COSENTYX® Connect Enrollment Tearsheet

A checklist to help patients understand the process of receiving their COSENTYX prescription and the resources available to them, as well as instructions on how to enroll in the COSENTYX Connect Personal Support Program.

COSENTYX Patient Insurance Brochure

Patient Insurance Brochure

Information to help patients navigate any changes in their insurance plan and avoid disruptions in their COSENTYX treatment.

Instructional videos

Video Thumbnail

COSENTYX Onboarding Video

This video walks through the 3 easy steps patients should keep in mind when getting started on COSENTYX.

Video Thumbnail

Supplemental Sensoready Pen Injection Demonstration Video

A step-by-step video with visual instructions on how patients should use the Sensoready pen.

Video Thumbnail

Supplemental Prefilled Syringe Injection Demonstration Video

A step-by-step video with visual instructions on how patients should use the COSENTYX prefilled syringe.

Video Thumbnail

Medisafe Patient Video

An overview of how the Medisafe app can guide patients through their first year of COSENTYX.

COSENTYX YouTube Channel

See more COSENTYX patient videos on our YouTube page.

Key contacts

Patients can use the information below to reach out with questions about their treatment or support.

Monday - Friday, 8:00 AM - 8:30 PM ET

T: 1-844-COSENTYX (1-844-267-3689)

F: 1-844-666-1366

Monday - Friday, 8:00 AM - 8:30 PM ET

T: 1-844-COSENTYX (1-844-267-3689)

Medisafe app was developed by Medisafe Project Ltd.

Reference: 1. Rudwaleit M, van der Heijde D, Landew´┐Ż R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777-783.

INDICATIONS

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

WARNINGS AND PRECAUTIONS

Infections

INDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.

COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis.

COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis.

COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients in COSENTYX. Cases of anaphylaxis have been reported during treatment with COSENTYX.

WARNINGS AND PRECAUTIONS

Infections

COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in COSENTYX treated subjects compared to placebo-treated subjects. In placebo-controlled clinical trials in subjects with moderate to severe plaque psoriasis, higher rates of common infections, such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%) and mucocutaneous infections with candida (1.2% versus 0.3%) were observed with COSENTYX compared with placebo. A similar increase in risk of infection was seen in placebo-controlled trials in subjects with psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. The incidence of some types of infections appeared to be dose-dependent in clinical studies. In the postmarketing setting, serious and some fatal infections have been reported in patients receiving COSENTYX.

Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection.

Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, monitor the patient closely and discontinue COSENTYX until the infection resolves.

Pre-treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Avoid administration of COSENTYX to patients with active TB infection. Initiate treatment of latent TB prior to administering COSENTYX. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients closely for signs and symptoms of active TB during and after treatment.

Inflammatory Bowel Disease

Caution should be used when prescribing COSENTYX to patients with inflammatory bowel disease. Exacerbations, in some cases serious, occurred in COSENTYX treated subjects during clinical trials in plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. In addition, new onset inflammatory bowel disease cases occurred in clinical trials with COSENTYX. In an exploratory trial in 59 subjects with active Crohn’s disease, there were trends toward greater disease activity and increased adverse events in the secukinumab group as compared to the placebo group. Patients who are treated with COSENTYX should be monitored for signs and symptoms of inflammatory bowel disease.

Hypersensitivity Reactions

Anaphylaxis and cases of urticaria occurred in COSENTYX treated subjects in clinical trials. If an anaphylactic or other serious allergic reaction occurs, administration of COSENTYX should be discontinued immediately and appropriate therapy initiated.

The removable caps of the COSENTYX Sensoready® pen and the COSENTYX 1 mL and 0.5 mL prefilled syringes contain natural rubber latex, which may cause an allergic reaction in latex-sensitive individuals. The safe use of the COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.

Immunizations

Prior to initiating therapy with COSENTYX, consider completion of all age appropriate immunizations according to current immunization guidelines. COSENTYX may alter a patient’s immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX.

Non-live vaccinations received during a course of COSENTYX may not elicit an immune response sufficient to prevent disease.

MOST COMMON ADVERSE REACTIONS

Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.

Please see full Prescribing Information, including Medication Guide.